More on cutaneous reactions to recombinant cytokine therapy.
Le Gal
F A
FA
Paul
C
C
Chemaly
P
P
Dubertret
L
L
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D007371:Interferon-gamma / Q000009:adverse effects*; D007376:Interleukin-2 / Q000009:adverse effects; D008545:Melanoma / Q000473:pathology / Q000556:secondary / Q000628:therapy; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy; D014820:Vitiligo / Q000209:etiology*
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma